Related Experiment Video
Updated: Jun 24, 2026
14:34
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Polydatin as a Mixed-Type Inhibitor of CYP1B1: An Integrative Study Combining Enzymatic Assays and Molecular
Liwei Jia1, Lei Zhou1, Jinyue Lu1
1School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Journal of Biochemical and Molecular Toxicology
|June 23, 2026
Summary
Polydatin effectively inhibits Cytochrome P450 1B1 (CYP1B1), an enzyme often upregulated in tumors. This study explored polydatin
Area of Science:
- Biochemistry
- Pharmacology
- Computational Chemistry
Background:
- Cytochrome P450 1B1 (CYP1B1) is frequently overexpressed in various cancers, presenting a potential therapeutic target.
- Polydatin, a natural compound, exhibits diverse pharmacological effects, warranting investigation into its interaction with cancer-related enzymes.
Purpose of the Study:
- To investigate the inhibitory potential of polydatin against CYP1B1.
- To elucidate the binding mechanism and assess the drug-like properties of polydatin for potential cancer therapy applications.
Main Methods:
- Enzyme inhibition assays were performed to quantify polydatin's effect on CYP1B1 activity.
- Molecular docking and molecular dynamics simulations were employed to analyze the binding interactions.
- ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) predictions were conducted to evaluate pharmacokinetic properties.
Main Results:
- Polydatin demonstrated potent inhibition of CYP1B1 with an IC50 value of 0.11 ± 0.01 μM.
- Kinetic analysis revealed a mixed-type inhibition pattern.
- Molecular dynamics simulations confirmed the stability of the CYP1B1-polydatin complex, and ADMET analysis indicated favorable drug-like characteristics with a low risk of CYP-mediated drug-drug interactions.
Conclusions:
- Polydatin acts as a potent mixed-type inhibitor of CYP1B1.
- The computational analyses support a stable binding interaction between polydatin and CYP1B1.
- Polydatin possesses acceptable drug-like properties, suggesting its potential as a lead compound for further pharmacological development in cancer research.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...